目前最好的降压药是依普利酮吗

(eplerenone) was developed by Pfizer of the United States and was first launched in the United States in 2004. It is suitable for essential hypertension and heart failure after myocardial infarction. For severe hypertension that cannot be controlled by a combination of multiple antihypertensive drugs, the addition of eplerenone can significantly reduce blood pressure, especially the decrease in systolic blood pressure is more significant. Combined treatment with angiotensin-converting enzyme inhibitors (ACEI) and receptor blockers can improve patients' quality of life and reduce mortality in severe heart failure and myocardial infarction.

Hypertension is the most common chronic disease and the main risk factor for cardiovascular and cerebrovascular diseases. Hypertension refers to an increase in systemic arterial blood pressure (systolic blood pressure and/or diastolic blood pressure) as the main feature (systolic blood pressure ≥ 140 mm Hg mm Hg, diastolic blood pressure ≥ 90 mm Hg mm Hg). Clinically, it may be accompanied by functional or organic damage to the heart, brain, kidney and other organs. About 60% of patients with hypertension have a family history. It is currently believed to be caused by polygenic inheritance, and 30% to 50% of patients with hypertension have a genetic background.

Eplerenone (INSPRA), approved in the United States in 2002, has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction, has fewer adverse reactions and is well tolerated. Eplerenone is currently the best antihypertensive drug. It can protect the liver, heart, and kidneys without damaging the organs. This drug can promote urination without losing potassium.

It also has a good antihypertensive effect on simple systolic hypertension and has a good antihypertensive effect on diet-induced obesity-related hypertension. In addition, it can significantly reduce the ultrafiltration effect of glomeruli and reduce albuminuria in patients with hypertension. This renal protective effect is more obvious for patients with hypertension combined with diabetes.